Determining the effectiveness of torasemide and furosemide in heart failure - Design of a randomised comparison using the Regenstrief Medical Record System

被引:12
作者
Murray, MD
Tierney, WM
Brater, DC
机构
[1] Purdue Univ, Sch Pharm, Dept Pharm Practice, Indianapolis, IN USA
[2] Indiana Univ, Med Ctr, Regenstrief Hlth Ctr, Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA
[3] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA
[4] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA
关键词
D O I
10.2165/00044011-199816010-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: A state-of-the-art clinical computing system was investigated to test the hypothesis of whether a completely and predictably absorbed loop diuretic (torasemide) offers clinical advantages over a diuretic that is poorly and erratically absorbed (furosemide). Patients: We enrolled 234 patients with heart failure into this randomised, prospective, open-label study of the effectiveness and cost effectiveness of torasemide and furosemide with a comprehensive electronic medical record called the Regenstrief Medical Record System (RMRS) serving as the primary data repository. Methods: The RMRS contained patient data for.physician visits, emergency department visits, hospitalisations, laboratory tests, prescription medications, and in- and outpatient service charges. Because these patient data were captured during the course of routine care, there was much efficiency in study data collection and few associated costs. Before the study began, ready access to the RMRS data permitted characterisation of the target study population and an accurate sample size calculation. During the study, programs contained within the RMRS identified patients for recruitment, preserved randomisation, and alerted investigators to important patient events. Quality-of-life instruments programmed into notebook computers were loaded with available RMRS data and then supplemented with primary collection data, thereby permitting paperless data entry. Conclusion: The computing infrastructure used for this study has permitted us to examine an interface between clinical pharmacology and outcomes research within the realm of medical informatics.
引用
收藏
页码:45 / 52
页数:8
相关论文
共 18 条
[1]   CLINICAL AND ECONOMIC-FACTORS IN THE TREATMENT OF CONGESTIVE-HEART-FAILURE [J].
ANDREWS, R ;
COWLEY, AJ .
PHARMACOECONOMICS, 1995, 7 (02) :119-127
[2]   CHRONIC CONGESTIVE-HEART-FAILURE - WHERE HAVE WE BEEN - WHERE ARE WE HEADING [J].
APPLEFELD, MM .
AMERICAN JOURNAL OF MEDICINE, 1986, 80 (2B) :73-77
[3]  
Brater D C, 1991, Drugs, V41 Suppl 3, P14
[4]   Benefits and risks of torasemide in congestive heart failure and essential hypertension [J].
Brater, DC .
DRUG SAFETY, 1996, 14 (02) :104-120
[5]   TORASEMIDE - AN UPDATE OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY [J].
DUNN, CJ ;
FITTON, A ;
BROGDEN, RN .
DRUGS, 1995, 49 (01) :121-142
[6]   TORASEMIDE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL [J].
FRIEDEL, HA ;
BUCKLEY, MMT .
DRUGS, 1991, 41 (01) :81-103
[7]   RENAL AND EXTRARENAL SITES OF ACTION OF DIURETICS [J].
GIEBISCH, G ;
KLEINROBBENHAAR, G ;
KLEINROBBENHAAR, J ;
RATHEISER, K ;
UNWIN, R .
CARDIOVASCULAR DRUGS AND THERAPY, 1993, 7 :11-21
[8]  
*IMS AM LTD, PPLYM M PA
[9]  
Kruck F, 1991, Drugs, V41 Suppl 3, P60
[10]  
MCDONALD CJ, 1992, M D COMPUT, V9, P206